Current modalities of accelerated partial breast irradiation

John A. Cox, Todd Swanson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The benefits of adjuvant whole-breast irradiation (WBI) after breast-conserving surgery are well established and WBI is a standard of care. In selected patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has emerged as an alternative treatment option to WBI. Early trials of APBI have demonstrated an excellent local control rate and an associated good-to-excellent cosmetic outcome. APBI can reduce both the treatment volume and overall treatment time of adjuvant radiation therapy, which potentially overcomes logistical barriers associated with WBI that have previously prevented eligible women from pursuing breast-conserving therapy. Likewise, the addition of new modalities for APBI delivery has increased the number of patients who might be eligible for this adjuvant treatment - in the setting of breast-conserving surgery - despite the limited availability of long-term data on APBI outcomes compared to historical WBI outcomes. Ongoing phase III trials aim to compare APBI with WBI and also point the practitioner to the appropriate APBI patient selection criteria. Here, we review available modalities, patient selection criteria and consensus guideline recommendations, and current controversies in APBI.

Original languageEnglish (US)
Pages (from-to)344-356
Number of pages13
JournalNature Reviews Clinical Oncology
Volume10
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Breast
Patient Selection
Segmental Mastectomy
Therapeutics
Standard of Care
Cosmetics
Radiotherapy
Guidelines
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Current modalities of accelerated partial breast irradiation. / Cox, John A.; Swanson, Todd.

In: Nature Reviews Clinical Oncology, Vol. 10, No. 6, 06.2013, p. 344-356.

Research output: Contribution to journalArticle

@article{8b2884d0e80f4b9abcd0bdf8d0153900,
title = "Current modalities of accelerated partial breast irradiation",
abstract = "The benefits of adjuvant whole-breast irradiation (WBI) after breast-conserving surgery are well established and WBI is a standard of care. In selected patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has emerged as an alternative treatment option to WBI. Early trials of APBI have demonstrated an excellent local control rate and an associated good-to-excellent cosmetic outcome. APBI can reduce both the treatment volume and overall treatment time of adjuvant radiation therapy, which potentially overcomes logistical barriers associated with WBI that have previously prevented eligible women from pursuing breast-conserving therapy. Likewise, the addition of new modalities for APBI delivery has increased the number of patients who might be eligible for this adjuvant treatment - in the setting of breast-conserving surgery - despite the limited availability of long-term data on APBI outcomes compared to historical WBI outcomes. Ongoing phase III trials aim to compare APBI with WBI and also point the practitioner to the appropriate APBI patient selection criteria. Here, we review available modalities, patient selection criteria and consensus guideline recommendations, and current controversies in APBI.",
author = "Cox, {John A.} and Todd Swanson",
year = "2013",
month = "6",
doi = "10.1038/nrclinonc.2013.65",
language = "English (US)",
volume = "10",
pages = "344--356",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Current modalities of accelerated partial breast irradiation

AU - Cox, John A.

AU - Swanson, Todd

PY - 2013/6

Y1 - 2013/6

N2 - The benefits of adjuvant whole-breast irradiation (WBI) after breast-conserving surgery are well established and WBI is a standard of care. In selected patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has emerged as an alternative treatment option to WBI. Early trials of APBI have demonstrated an excellent local control rate and an associated good-to-excellent cosmetic outcome. APBI can reduce both the treatment volume and overall treatment time of adjuvant radiation therapy, which potentially overcomes logistical barriers associated with WBI that have previously prevented eligible women from pursuing breast-conserving therapy. Likewise, the addition of new modalities for APBI delivery has increased the number of patients who might be eligible for this adjuvant treatment - in the setting of breast-conserving surgery - despite the limited availability of long-term data on APBI outcomes compared to historical WBI outcomes. Ongoing phase III trials aim to compare APBI with WBI and also point the practitioner to the appropriate APBI patient selection criteria. Here, we review available modalities, patient selection criteria and consensus guideline recommendations, and current controversies in APBI.

AB - The benefits of adjuvant whole-breast irradiation (WBI) after breast-conserving surgery are well established and WBI is a standard of care. In selected patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has emerged as an alternative treatment option to WBI. Early trials of APBI have demonstrated an excellent local control rate and an associated good-to-excellent cosmetic outcome. APBI can reduce both the treatment volume and overall treatment time of adjuvant radiation therapy, which potentially overcomes logistical barriers associated with WBI that have previously prevented eligible women from pursuing breast-conserving therapy. Likewise, the addition of new modalities for APBI delivery has increased the number of patients who might be eligible for this adjuvant treatment - in the setting of breast-conserving surgery - despite the limited availability of long-term data on APBI outcomes compared to historical WBI outcomes. Ongoing phase III trials aim to compare APBI with WBI and also point the practitioner to the appropriate APBI patient selection criteria. Here, we review available modalities, patient selection criteria and consensus guideline recommendations, and current controversies in APBI.

UR - http://www.scopus.com/inward/record.url?scp=84878525208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878525208&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2013.65

DO - 10.1038/nrclinonc.2013.65

M3 - Article

C2 - 23629470

AN - SCOPUS:84878525208

VL - 10

SP - 344

EP - 356

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 6

ER -